Fig. 1.

A PRAME^100−108 CTL clone effectively lyses PRAME expressing target cells. a T2 cell binding assay to demonstrate stabilisation of HLA-A0201 on surface of T2 cells by named peptides with immunodominant Flu matrix peptide as positive control. b PRA^100−108-specific clone 10D shows high specific killing of peptide-pulsed T2 cells. E:T ratio 10:1. c CTL clone 10D shows relatively low avidity as determined by killing of T2 cells pulsed with increasing concentrations of PRA^100−108 peptide. d Killing by clone 10D as determined by chromium release assay, of cell lines pulsed with indicated peptides or pretreated with HLA-A0201 blocking antibody (A2). Ig denotes isotype control. T2 cells pulsed with PRA^100−108 as positive control. e 18 h chromium release killing of SW480 and Raji cells lines transfected with PRAME or empty vector in presence of specific HLA-A0201 blocking antibody (A2) or isotype control (Ig). Error bars denote mean ± SEM. All chromium assays were performed over 4 h